Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. Issue 4 (October 2020)

• Record Type: Journal Article
• Authors: Russo, Vincenzo; Cardillo, Giuseppe; Viggiano, Giuseppe Vito; Mangiacapra, Sara; Cavalli, Antonella; Fontanella, Andrea; Agrusta, Federica; Bellizzi, Annamaria; Amitrano, Maria; Iannuzzo, Mariateresa; Sacco, Chiara; Lodigiani, Corrado; Di Micco, Pierpaolo
• Is Part Of: Journal of cardiovascular pharmacology. Volume 76:Issue 4(2020)
• Publication Date: 2020-10
• Subjects: Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000000893
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract : Abstract: The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COVID-19. The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients. The incidence of pulmonary embolism, deep venous thrombosis, major bleeding (MB), clinically relevant non-MB, acute respiratory distress syndrome, and in-hospital mortality was compared between patients on fondaparinux versus enoxaparin therapy. The 2 groups were homogeneous for demographic, laboratory, and clinical characteristics. In a median follow-up of 28 (IQR: 12–45) days, no statistically significant difference in venous thromboembolism (14.5% vs. 5.3%; P = 0.20), MB and clinically relevant non-MB (3.2% vs. 5.3%, P = 0.76), ARDS (17.7% vs. 15.8%; P = 0.83), and in-hospital mortality (9.7% vs. 10.5%; P = 0.97) has been shown between the enoxaparin group versus the fondaparinux group. Our preliminary results support the hypothesis of a safe and effective use of fondaparinux among patients with COVID-19 hospitalized in internal medicine units.